BlackRock Group’s Karyopharm Therapeutics KPTI Stock Holding History

BlackRock Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$66K	Buy	466 +25	+6%	+$3.38K	﹤0.01%	2886
2016 Q3	$64K	Buy	441 +11	+3%	+$1.32K	﹤0.01%	2882
2016 Q2	$43K	Sell	430 -4	-0.9%	-$520	﹤0.01%	2941
2016 Q1	$58K	Buy	434 +225	+108%	+$24.8K	﹤0.01%	2892
2015 Q4	$41K	Sell	209 -5	-2%	-$1.08K	﹤0.01%	2851
2015 Q3	$34K	Buy	214 +100	+88%	+$26.7K	﹤0.01%	2909
2015 Q2	$46K	Buy	+114	New	+$49.3K	﹤0.01%	2875
2015 Q1	–	Sell	-13,994	Closed	-$7.86M	–	2869
2014 Q4	$7.86M	Sell	13,994 -1,394	-9%	-$792K	﹤0.01%	1015
2014 Q3	$8.06M	Sell	15,388 -46	-0.3%	-$26K	﹤0.01%	999
2014 Q2	$10.8M	Buy	15,434 +6,366	+70%	+$2.96M	0.01%	928
2014 Q1	$4.2M	Buy	9,068 +3,508	+63%	+$1.78M	﹤0.01%	1179
2013 Q4	$1.91M	Buy	+5,560	New	+$1.54M	﹤0.01%	1551

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Group's KPTI Position: Q4 2016 in Review

BlackRock Group increased its Karyopharm Therapeutics (KPTI) stake by 5.7% in Q4 2016, buying an estimated $3.38K and bringing the position to 466 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #2886.

BlackRock Group first reported a position in KPTI in Q4 2013 and has held it in 12 quarters since. The position peaked at $10.8M in Q2 2014. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

BlackRock Group held 466 shares of Karyopharm Therapeutics worth $66K as of Q4 2016.
BlackRock Group bought 25 Karyopharm Therapeutics shares in Q4 2016, an estimated $3.38K.
Karyopharm Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2886 holding.
BlackRock Group first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 12 quarters since.
BlackRock Group's Karyopharm Therapeutics position peaked at $10.8M in Q2 2014.
86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.